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Insulin-like growth factor-1 (IGF-1) is an important anabolic hormone that decreases with
age. In the past two decades, extensive research has determined that the reduction
in IGF-1 is an important component of the age-related decline in cognitive function in
multiple species including humans. Deﬁciency in circulating IGF-1 results in impairment
in processing speed and deﬁciencies in both spatial and working memory. Replacement
of IGF-1 or factors that increase IGF-1 to old animals and humans reverses many of
these cognitive deﬁcits. Despite the overwhelming evidence for IGF-1 as an important
neurotrophic agent, the speciﬁc mechanisms through which IGF-1 acts have remained
elusive. Recent evidence indicates that IGF-1 is both produced by and has important actions
on the cerebrovasculature as well as neurons and glia. Nevertheless, the speciﬁc regulation
and actions of brain- and vascular-derived IGF-1 is poorly understood. The diverse effects
of IGF-1 discovered thus far reveal a complex endocrine and paracrine system essential
for integrating many of the functions necessary for brain health. Identiﬁcation of the
mechanisms of IGF-1 actions will undoubtedly provide critical insight into regulation of
brain function in general and the causes of cognitive decline with age.
Keywords: aging, cognitive decline, IGF-1, vasculature
INTRODUCTION
Cognitive decline is a common complication of aging that
includes alterations in a variety of brain functions including,
but not limited to, reductions in processing speed, induc-
tive reasoning, and spatial learning and memory (Hedden and
Gabrieli, 2004). Impairment of these functions is closely asso-
ciated with a decrease in both health-span and independence.
Over the past two decades, research studies have focused on
hippocampal-dependent spatial learning and memory since they
are dramatically impaired in aging subjects experiencing cogni-
tive decline and can be important factors in disability (Hedden
and Gabrieli, 2004). Age-related deﬁcits in spatial learning and
memory increase in prevalence and severity with common con-
ditions such as type 2 diabetes, hypertension, and heart disease
(Dahle et al., 2009; Okonkwo et al., 2010). Additionally, as the
quality and availability of health care in developed countries con-
tinue to improve, the aged population is expected to increase
(Social Science Data Analysis Network 2010). An unfortunate
consequence of this is a rise in the prevalence of age-related
cognitive decline. Incidence of cognitive impairment is approx-
imately 1 in 24 at the age of 65 but increases to 1 in 3 by the
age of 80 (Alzheimer’s Association). As such, greater emphasis
needs to be placed on understanding, preventing, and treat-
ing cognitive impairment. The neurobiological basis of a subset
of cognitive impairment, which occurs in the absence of neu-
ronal cell death or neuropathology (Rapp and Gallagher, 1996;
Rasmussen et al., 1996; Rapp et al., 2002), remains to be deter-
mined but likely involves regions of the brain associated with
learning and memory including the hippocampus and prefrontal
cortical regions. Within these regions impaired synaptic signaling
is especially affected by aging (reviewed in Hof and Morri-
son, 2004) and is likely the ﬁnal common pathway to cognitive
impairment.
Impaired hippocampal function associated with aging occurs
in many species including humans (Schaie, 1989), monkeys
(Rapp and Amaral, 1989), rats (Rapp and Gallagher, 1996),
and mice (Gower and Lamberty, 1993). Decreased expression
of synaptic machinery, increased oxidative stress, decreased glu-
cose metabolism, and aberrant protein folding and trafﬁcking are
characteristic structural and molecular changes that accompany
this phenomenon (reviewed in VanGuilder and Freeman, 2011).
Electrophysiological studies of hippocampal function demon-
strate that signaling disruptions occur in animals with spatial
learning and memory impairments. These electrophysiological
characteristics also are associated with impaired neurotransmit-
ter synthesis and receptor signaling, dysregulated neuronal gene
and protein expression, and atypical synapse morphology (Poe
et al., 2001; Shi et al., 2005; Burke and Barnes, 2006; Liu et al.,
2008). Despite our understanding of the cellular changes that con-
tribute to cognitive decline, the precise causes for the changes in
brain function are unknown and represent an important challenge
for neuroscientists. We, and others, have proposed that circulat-
ing factors inﬂuenced by the aging process have the potential to
inﬂuence brain function either indirectly through actions on the
cerebrovasculature or directly through actions on neurons and
glia.
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One of the factors that have profound actions on the brain is
insulin-like growth factor-1 (IGF-1). Circulating IGF-1 is derived
from the liver and is regulated by pulsatile secretion of pitu-
itary growth hormone (Sonntag et al., 2005). Although IGF-1
is an important anabolic hormone throughout the body, the
importance of IGF-1 in normal development of the brain is
demonstrated by the striking central nervous system (CNS) phe-
notype of IGF-1 knockout mice. igf-1 gene disruption results in
reduced brain size, CNS hypomyelination and loss of hippocam-
pal granule and striatal parvalbumin-containing neurons (Beck
et al., 1995) suggesting that IGF-1 has a critical role in CNS devel-
opment and function. Consistent with this hypothesis, transgenic
mice overexpressing IGF-1 have a signiﬁcantly larger brain as well
as increased myelin content (Carson et al., 1993). IGF-1 has a
major role in neuronal development based on studies that IGF-
1 inﬂuences neuronal stem cell differentiation (Vicario-Abejon
et al., 2003), axonal path ﬁnding (Scolnick et al., 2008), and den-
dritic outgrowth (Cheng et al., 2003; Cao et al., 2011). Studies
on the role of the IGF-1 receptor are consistent with the critical
effects of IGF-1 on brain development. A homozygous null muta-
tion of the IGF-1 receptor causes neonatal lethality in mice (Liu
et al., 1993; Holzenberger et al., 2003) and speciﬁc brain IGF-1
receptor knockout mice are viable but exhibit severe developmen-
tal abnormalities including dwarﬁsm and microcephaly (Kappeler
et al., 2008).
In response to decreases in growth hormone levels, IGF-1 con-
centrations decrease substantially with age (Sonntag et al., 2005).
Importantly, studies indicate a close temporal association between
the decrease in these circulating hormones and spatial and work-
ing memory performance in both rodent and human models. In
humans, the importance of IGF-1 for normal body function as
well as brain function has been recognized since the mid-1990s
(Johansson et al., 1995; Nyberg and Burman, 1996; Burman and
Deijen, 1998) and additional information regarding the relation-
ship between IGF-1 and brain function has recently become even
more apparent (Ross, 2005; Aleman and Torres-Aleman, 2009).
In adults, circulating IGF-1 deﬁciency is associated with cogni-
tive dysfunction (Deijen et al., 1996; Lijfﬁjt et al., 2003; van Dam,
2005; Koltowska-Haggstrom et al., 2006) that can be reversed by
increasing circulating IGF-1 levels (Sartorio et al., 1995; Deijen
et al., 1998; Golgeli et al., 2004; Oertel et al., 2004; Arwert et al.,
2006). Rodents have a similar decrease in circulating IGF-1 lev-
els with age and intra-cerebroventricular (icv) IGF-1 replacement
to older F344xBN rats, which increases concentrations of IGF-1
in the hippocampus to levels found in young animals, reverses
these cognitive deﬁcits (Trejo et al., 2007). A similar reversal of
age-related memory deﬁcits also occurs in response to periph-
eral administration of growth hormone (Sonntag et al., 2005) or
injection of growth hormone releasing hormone (GHRH) that
increases both growth hormone and IGF-1 levels (Thornton et al.,
2000). The relevance of circulating IGF-1 to CNS function is per-
haps best demonstrated in liver-speciﬁc IGF-1 knockout mice that
exhibit a 60% reduction of IGF-1 levels at an early age (compara-
ble to the decreases observed in aged rats and humans). These
animals exhibit a reduction in learning and memory and also
have a deﬁcit in perforant path long-term potentiation (LTP; a
molecular correlate of learning and memory) that results from the
selective loss of excitatory inputs (Trejo et al., 2007). In addition to
effects on learning and memory, IGF-1 has been shown to increase
positive affective states in rodents (assessed by rough and tumble
play and hedonic ultrasonic vocalizations). These studies lead to
the conclusion that deﬁciencies in IGF-1 not only affect learn-
ing and memory but may have a role in the onset of depression
(Burgdorf et al., 2010). Thus, there is now extensive evidence that
in many species the age-related decrease in circulating IGF-1 is
an important factor that regulates brain function as well as brain
aging.
The purpose of this review is to assess the complex roles of IGF-
1 in the genesis of cognitive impairment with age. Although the
conclusion from numerous studies is that IGF-1 deﬁciency is an
important contributing factor in deﬁcits in learning and memory
both in aged humans as well as rodent models of aging, a consen-
sus for a single, speciﬁc action of IGF-1 has not emerged. Rather
the data indicate that IGF-1 has both important vascular and neu-
rotrophic actions that support multiple aspects of brain health.
Here, we review data on the actions of IGF-1 on cerebrovascu-
lar structure and function, glia, and neurons and speciﬁcally on
synaptic function. The emerging studies indicate that IGF-1 acts
on all these cells and tissues to regulate brain health. It should be
noted that this review does not address the potentially important
relationship between IGF-1, age-related cognitive dysfunction and
Alzheimer’s disease. Although Alzheimer’s disease is closely asso-
ciated with aging and in the early stages of the disease share many
behavioral similarities, the molecular mechanisms for these two
conditions diverge at some point during the progression of the dis-
ease. Despite these separate mechanisms, the molecular changes
that occur in the brain with age remain the primary risk factor
for Alzheimer’s disease. For additional information on this topic
please refer to recent reviews (Selkoe, 2012; Krstic and Knuesel,
2013; Wirth et al., 2013).
CEREBROVASCULAR DYSFUNCTION AND COGNITIVE
DECLINE IN THE ELDERLY: ROLE OF AGE-RELATED
IGF-1 DEFICIENCY
Cerebrovascular alterations play a key role in various cognitive dis-
orders in the elderly, including post-stroke dementia,multi-infarct
dementia, subcortical ischemic vascular disease and dementia,
mild cognitive impairment, and even Alzheimer’s disease (Gore-
lick et al., 2011). Cerebrovascular alterations are also likely to
exacerbate cognitive decline in elderly patients with metabolic
diseases, hypertension, other vascular risk factors (e.g., hyperho-
mocysteinemia) as well as lifestyle factors (e.g., lack of exercise).
The cerebrovascular mechanisms affected by aging that promote
neuronal dysfunction and cognitive decline are likely multifacto-
rial. These include, but are not limited to, (a) impaired delivery of
oxygen and nutrients to neurons (due to large vessel disease and/or
structural and functional alterations of the cerebral microcircu-
lation), (b) endothelial dysfunction and impaired neurovascular
coupling, (c) impaired autoregulation, (d) disruption of the
blood–brain barrier (BBB) resulting in leakage of plasma-derived
pro-inﬂammatory factors, endothelial activation, and entry of
inﬂammatory cells into the brain, and (e) endothelial senescence
that leads to altered secretion of endothelium-derived trophic
factors, impaired neurogenic niches and increased secretion of
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pro-inﬂammatory cytokines and matrix metalloproteinases from
the microvascular endothelium. In addition, abnormal function
of the glymphatic system, a paravascular pathway believed to be
essential for clearance of solutes and waste products (including
amyloid beta, Aβ) from the brain (Iliff et al., 2012), may also
contribute to cognitive decline in the elderly. Despite signiﬁcant
advances in recent years, the mechanisms underlying age-related
cerebrovascular alterations still are not completely understood
(Ungvari et al., 2010b).
Investigators have recognized that circulating IGF-1 is an
important vascular protective factor and that the age-related
decline in IGF-1 levels contribute to vascular aging (reviewed
recently in Ungvari and Csiszar, 2012). Epidemiological stud-
ies clearly indicate that growth hormone and IGF-I deﬁciency
in humans are associated with premature atherosclerosis and
increased risk for cardiovascular and cerebrovascular diseases
(Rosen and Bengtsson, 1990; Bates et al., 1996; Spallarossa
et al., 1996; Bulow et al., 1997; Tomlinson et al., 2001; Juul
et al., 2002; Roubenoff et al., 2003; van den Beld et al., 2003;
Vasan et al., 2003; Conti et al., 2004; Laughlin et al., 2004; Ung-
vari and Csiszar, 2012). Because of the important association
between age-related cerebrovascular impairments and cogni-
tive decline, the potential neuroprotective effects of IGF-1 are
considered as partially mediated through cerebromicrovascular
protection.
CEREBROMICROVASCULAR RAREFACTION AND IMPAIRED REGIONAL
BLOOD FLOW IN AGING: ROLE OF IGF-1 DEFICIENCY
Delivery of nutrients, clearance of metabolites, and exchange of
gases between theblood and tissues occurs almost exclusively in the
microcirculation. Thus, adequate blood perfusion via the micro-
circulatory network is essential for the integrity of tissues and
normal organ function. Previous studies demonstrate that aging
impairs regional cerebral blood ﬂow in humans (Martin et al.,
1991; Nakano et al., 2000), which certainly contributes to altered
neuronal function. As the nervous system ages, there is a sig-
niﬁcant rarefaction of the microvasculature in the hippocampus
and other regions of the brain involved in cognition and there
are structural changes in the vessels that remain (Sonntag et al.,
1997, 2000b; Khan et al., 2002; Riddle et al., 2003). It is thought
that microvascular rarefaction is a major factor underlying inad-
equate cerebral perfusion resulting in cognitive dysfunction in
the absence of, or preceding, neurodegeneration in the elderly.
The decline in regional cerebral blood ﬂow due to age-related
microvascular rarefaction likely reduces metabolic support for
neural signaling, especially when neuronal activity is high. In
addition, aging reduces microvascular plasticity and the ability of
the cerebral circulation to adapt to changes in metabolic demand
(Riddle et al., 2003). Importantly, recent studies demonstrate that
growth hormone supplementation, which signiﬁcantly elevates
circulating levels of IGF-1, substantially increases cortical vascular
density in older rats (Sonntag et al., 1997) and results in signiﬁcant
improvements of cognitive function (Lichtenwalner et al., 2001;
Poe et al., 2001; Khan et al., 2002; Ramsey et al., 2004; Sonntag
et al., 2005; Hua et al., 2008). Similar increases in cerebrovascu-
lar density are observed in mice infused with IGF-1(Lopez-Lopez
et al., 2004).
The mechanisms by which IGF-1 reverses/prevents microvas-
cular rarefaction and improves tissue blood supply are likely
multifaceted. On the basis of the available evidence it is possi-
ble to speculate that an increased rate of apoptosis in capillary
endothelial cells contributes to age-related microvascular rar-
efaction. Accordingly, both in aged laboratory rodents and in
non-human primates the prevalence of apoptotic endothelial cells
signiﬁcantly increases (Asai et al., 2000; Csiszar et al., 2004, 2007;
Pearson et al., 2008), at least in part, due to impaired bioavailabil-
ity of nitric oxide (NO), oxidative stress and/or chronic low-grade
inﬂammation (Csiszar et al., 2004, 2007). One well-recognized
action IGF-1 is suppression of apoptosis (Bailey-Downs et al.,
2012), likely by preserving the functional integrity of the mito-
chondria (Li et al., 2009). Additional studies are needed to test
whether augmentation of IGF-1 signaling in aging will also
exert anti-apoptotic actions in endothelial cells effect resulting
in the prevention or reversal of age-related cerebromicrovascular
rarefaction.
Another mechanism, which potentially contributes to
microvascular rarefaction is an age-related impairment of angio-
genesis (Rivard et al., 1999). IGF-1 is known to confer pro-
angiogenic effects, inducing proliferation of cerebromicrovascular
endothelial cells via a hypoxia-inducible factor-1 alpha (HIF-
1α) and vascular endothelial growth factor (VEGF)-dependent
pathway (Lopez-Lopez et al., 2004). Using various animal mod-
els of age-related cerebrovascular diseases it has been reported
that IGF-1, in addition to its direct neurotrophic effects, exerts
angiogenic effects and protects the brain from experimental
ischemic injury (Loddick et al., 1998; Guan et al., 2000, 2001;
Liu et al., 2001; Schabitz et al., 2001; Mackay et al., 2003; Lein-
ninger and Feldman, 2005). Previous studies indicate that IGF-
1 has a signiﬁcant role in cerebral angiogenesis both during
development and in adulthood (Conti et al., 2004; Lopez-Lopez
et al., 2004). Importantly, physical exercise, which is known
to increase cerebromicrovascular density in control mice, fails
to do so in mice with low serum IGF-1 (Lopez-Lopez et al.,
2004). Previous studies demonstrated that overexpression of IGF-
1 either before or after induction of cerebral ischemia enhance
neurovascular remodeling, increasing cerebromicrovascular den-
sity and improving functional outcomes in rodent models of
ischemic stroke (Zhu et al., 2008, 2009b). In contrast, disrup-
tion of IGF-1 signaling by an anti-IGF-1 antibody abrogates
peri-lesion microvascular growth in the brain (Lopez-Lopez et al.,
2004).
Age-related impairment of endothelial cell turnover due
to decreased number and impaired function of endothelial
progenitor cells may also negatively impact the microcircula-
tion. Importantly, age-dependent impairment of endothelial
progenitor cells was reported to be corrected by the growth
hormone-mediated increase in circulating IGF-1 (Thum et al.,
2007), which likely exerts beneﬁcial effects on the regen-
erative capacity of the cardiovascular system in the elderly.
Additionally, in vitro studies demonstrate that the presence
of sera from young rats (which have high IGF-1 levels)
in the culture medium improves the function of endothe-
lial progenitor cells isolated from aged rats (Zhu et al.,
2009a).
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VASCULAR OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION
IN AGING
Increased oxidative stress and endothelial dysfunction are char-
acteristics of vascular aging in general (Ungvari et al., 2010b).
Earlier studies demonstrated that up-regulation of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases with age pro-
motes oxidative stress in the cerebral microvasculature (Park et al.,
2007). Age-related oxidative stress impairs the bioavailability of
NO, which is responsible, at least in part, for impairment of
cerebromicrovascular function (Park et al., 2007) and may con-
tribute to microvascular rarefaction. This concept is supported
by studies indicating that rodents with genetically impaired NO
signaling (Kubis et al., 2002) or animals treated with NO synthe-
sis inhibitors (Frisbee, 2005) develop microvascular rarefaction
in the systemic circulation. Several lines of evidence suggest
that vascular oxidative stress and decreased NO bioavailability
results from IGF-1 deﬁciency. First, animal models of IGF-1
deﬁciency often exhibit increased reactive oxygen species (ROS)
production and decreased NO bioavailability, mimicking the vas-
cular aging phenotype (Csiszar et al., 2008; Ungvari et al., 2010a;
Bailey-Downs et al., 2012). Second, treatment of aged rats with
IGF-1up-regulates endothelialNOsynthase (eNOS) and improves
bioavailability of NO (Pu et al., 2008; Cittadini et al., 2009). IGF-1
treatment has similar effects in mouse models of accelerated vas-
cular aging (Sukhanov et al., 2007). Finally, in vitro IGF-1 reduces
ROS production and up-regulates eNOS in cultured endothelial
cells (Csiszar et al., 2008).
AGE-RELATED IMPAIRMENTS OF NEUROVASCULAR COUPLING
Neurovascular coupling is the mechanism that maintains an opti-
mal neuronal microenvironment by adjusting local blood ﬂow
to neuronal activity. Previous studies using an event-related
color-word matching Stroop task and functional near-infrared
spectroscopy demonstrated that neurovascular coupling declines
in the prefrontal cortex with age (Schroeter et al., 2003, 2007).
Similar conclusions were reached in studies using simultane-
ous recording of cerebral blood ﬂow velocity responses and
visual evoked potentials using graded visual contrasts (Zaletel
et al., 2005). The breakdown of the molecular communication
between neurons and microvessels and the resulting uncoupling
between metabolism and regional cerebral blood ﬂow likely con-
tribute to age-related cognitive impairment. Although the speciﬁc
mechanisms underlying age-related impairment of neurovascular
coupling are not completely understood, these effects are likely
associated with increased oxidative stress and endothelial dys-
function (Park et al., 2007). In addition, age-related changes in
astrocyte function, the extracellular matrix and innervation of
the vascular wall may also contribute to age-related impairment
of neurovascular coupling. IGF-1 was reported to regulate astro-
cyte function (Ni et al., 1997; Aberg et al., 2003), but the role of
IGF-1 deﬁciency in the age-related impairment of neurovascular
coupling remains elusive. Seminal studies by the Iadecola labora-
tory demonstrate that bioavailability of NO (Zhang et al., 1998;
Kazama et al., 2003, 2004; Park et al., 2005, 2007; Girouard et al.,
2007) determines the efﬁciency of neurovascular coupling. Since
IGF-1 has an important role in the regulation of microvascular
NO synthesis (see above), further studies are necessary to elucidate
the causal link between IGF-1 deﬁciency and impaired functional
hyperemia in aging.
AGE-RELATED CHANGES IN AUTOREGULATION OF CEREBRAL
BLOOD FLOW
Regulation of cerebral blood ﬂow depends on a complex interac-
tion between various regulatory mechanisms, including mechan-
otransduction of pressure/wall tension and shear stress, metabolic
factors, chemical factors (pCO2, pH.pO2), mediators released
from astrocytes and pericytes as well as neural control. Mecha-
nisms that respond to changes in pressure and blood ﬂow-related
shear stress are responsible for autoregulation of cerebral blood
ﬂow resulting in stable, constant cerebral perfusion despite
changes in systemic blood pressure. Autoregulation responds to
two different, bi-directional requirements; vasodilation and a
decrease in vascular resistance in the presence of decreasing blood
pressure (e.g., due to orthostatic hypotension) and vasoconstric-
tion and increased cerebrovascular resistance in response to sud-
den increases in blood pressure. The dilation and constriction of
cerebral vessels in response to changes in systemic blood pressure
is predominantly regulated by pressure- and ﬂow-sensitivemecha-
nisms (including 20-hydroxyeicosatetraenoic acid (20-HETE) and
transient receptor potential cation channels, subfamily C, mem-
ber 6 (TRPC6) channel-mediated increases in smooth muscle
[Ca2+]i) that are intrinsic to the vascular wall. Dysfunction of
cerebral autoregulation has multiple consequences. For example,
inadequate dilation in response to a decrease in blood pressure
can lead to ischemic damage, whereas insufﬁcient constriction of
proximal branches of the cerebrovascular tree permits increased
arterial pressure topenetrate thedistal portionof themicrocircula-
tion resulting in damage to the thin-walled arteriolar and capillary
microvessels. Such dysfunction is thought to contribute to vari-
ous pathophysiological conditions affecting the brain, including
Alzheimer-disease (Niwa et al., 2002).
Several lines of evidence suggest that aging per se impairs
autoregulation. For example, aging is associated with a higher
incidence of postural syncope, a common consequence of sud-
den blood pressure drop in the elderly (Campbell et al., 1990).
A larger postural reduction in cerebral cortical oxygenation and
more pronounced decline in mean blood ﬂow velocity in mid-
dle cerebral arteries are manifest in elderly as compared to
young individuals (Mehagnoul-Schipper et al., 2000; Lucas et al.,
2008). Both in elderly humans and aged rodents, failure of
static autoregulation to maintain constant cerebral blood ﬂow
during hypotension has been reported (Wollner et al., 1979; Lar-
taud et al., 1993). Clinical studies also suggest that aging impairs
autoregulatory protection mechanisms in response to high blood
pressure in the human brain (Castellani et al., 2006). Studies
from our own laboratory provide evidence that aged mice exhibit
pathological loss of cerebral autoregulatory protection, which
contributes to an exacerbation of hypertension-induced cere-
bromicrovascular injury (Toth, Csiszar, Sonntag, and Ungvari,
2012, unpublished observation). Downstream consequences of
cerebrovascular autoregulatory dysfunction with age may include
disruption of the BBB, neuroinﬂammation due to microglia acti-
vation, leakage of plasma-derived pro-inﬂammatory factors and
cognitive decline (Zlokovic, 2008).
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The age-relatedmechanism(s) that are responsible for impaired
autoregulation are not well understood. The existing evidence
supports the concept that in young animals activation of a
20-HETE/TRPC-dependent pathway and arterial remodeling con-
tribute to functional adaptation of cerebral arteries to hyper-
tension and that these adaptive responses are dysfunctional in
aging. It is possible that age-related IGF-1 deﬁciency exerts
an important role in maladaptation of cerebral arteries to
changes in the hemodynamic environment (Ungvari and Csiszar,
2012). For example, recent studies demonstrate that hyperten-
sion in IGF-1 deﬁcient mice is associated with impaired adaptive
changes in cerebral arterial myogenic constriction (Toth and
Ungvari, unpublished observation, 2012) mimicking the aging
phenotype. IGF-1 deﬁciency also results in down-regulation
of cytochrome P450 4A ω-hydroxylases [see Gene Expression
Omnibus (GEO) datasets GDS2019 and GDS1053], which pro-
duce 20-HETE. Further, IGF-1 has been shown to regulate calcium
inﬂux through TRP-channels (Kanzaki et al., 1999) and improves
microvascular autoregulation in chronic kidney disease (Lin et al.,
1998). Additional studies will be required to determine whether
IGF-1 treatment reverses autoregulatory defects that occur
with age.
ROLE OF BLOOD–BRAIN BARRIER DISRUPTION
The BBB is the physical and metabolic barrier between circulating
blood and brain tissue; a dynamic interface necessary for proper
function of the CNS. There is growing evidence that when the BBB
is disrupted the unique physicochemical milieu needed for neu-
ronal function is not maintained, which contributes to cognitive
decline (Zlokovic, 2008, 2011). Neurons and glia are highly sensi-
tive to the effects of circulating bioactive molecules that normally
do not cross an intact BBB. However, after disruption of the BBB
extravasation of serum components (including thrombin, plas-
min, ﬁbrinogen, and IgG) result in activation of microglia and
increased production of matrix metalloproteinases, inﬂammatory
cytokines and ROS producing damage to neurons as well as astro-
cytes andpericytes (Zlokovic,2008,2011). There is strong evidence
that aging per se causes disruption of the BBB both in humans
(Farrall and Wardlaw, 2009), laboratory rodents and non-human
primates (Mackic et al., 1998) and these alterations have been pro-
posed to contribute to chronic low-grade neuroinﬂammation. We
have recently demonstrated that age-dependent increases in BBB
permeability in mice in various regions of the brain (cortex, white
matter, hippocampus) are associated with microglia activation,
inﬂammation, and oxidative stress; an effect exaggerated by the
presence of hypertension (Toth P, Csiszar A, Sonntag WE, and
Ungvari Z, unpublished observation, 2012). Receptors for IGF-1
are abundantly expressed on cells that constitute the BBB and the
expression of tight junction proteins necessary for proper BBB
function (e.g., zonula occludens-1, ZO-1) appear to be regulated
by IGF-1 in cultured cells (Ko et al., 2009). Nevertheless, the role of
IGF-1 deﬁciency in age-related disruption of the BBB is not com-
pletely understood. Previous studies demonstrate that endothelial
cell-speciﬁc knockout of the IGF-1 receptor does not lead to signif-
icant BBB disruption (Kondo et al., 2004). In contrast, our recent
ﬁndings demonstrate that although liver-speciﬁc knockdown of
IGF-1 (Igf1f /f +MUP-iCre-AAV8) does not cause BBBdisruption
under baseline conditions, it exacerbates BBB disruption elicited
by hypertension, mimicking the aging phenotype (Toth P, Csiszar
A, Sonntag WE, and Ungvari Z, unpublished observation, 2012).
AGING OF GLIA AND THE ROLE OF IGF-1
Glial cells including astrocytes, microglia, and oligodendrocytes
have a vital role in regulating neurovascular communication and
neuron survival. In addition to their well-known role as a buffer
of the synaptic space, astrocytes release a variety of regulatory
substances that modulate both vasculature and neurons (Pfrieger
and Barres, 1997; Allen and Barres, 2005; Koehler et al., 2006; Bar-
res, 2008; Petzold and Murthy, 2011). Astrocytes contribute to the
structure and integrity of the BBB and are known to regulate both
cerebral bloodﬂowaswell as the ﬂux of cerebrospinal ﬂuid into the
brain (Abbott,2002;Anderson andNedergaard,2003;Abbott et al.,
2006; Takano et al., 2006; Iliff et al., 2012). Because astrocytes have
a key role in maintaining homeostasis within the brain, it is easy
to appreciate how alterations in astrocyte function can have a dra-
matic impact on neuronal physiology. Recently, our lab reported
an increase in reactive astrocytes in aged rats (VanGuilder et al.,
2011a). This is consistent with previous studies indicating the up-
regulation of glial ﬁbrillary acidic protein (GFAP) and vimentin
(both intermediate ﬁlament proteins within astrocytes) mRNA
and protein expression in aged rodents and humans (Nichols
et al., 1993; David et al., 1997; Porchet et al., 2003). While several
aspects of astrocyte physiology remain unexplored in aged ani-
mals, cytokine production, speciﬁcally the production of tumor
necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and mono-
cyte chemotactic protein-1 (MCP-1), is known to be elevated in
aging astrocytes (Campuzano et al., 2009; Cowley et al., 2012).
Whether the loss of IGF-1 contributes to these age-related changes
in astrocyte number and function is unknown; however, recent
studies suggest that IGF-1 has a critical role in regulating astro-
cytic activity. In a model of amyotrophic lateral sclerosis (ALS),
IGF-1 treatment, acting speciﬁcally through astrocytes, reduced
neurotoxicity and rescued the disease-associated neurite retrac-
tion (Dodge et al., 2008). These results provide some of the ﬁrst
evidence that the age-induced loss of IGF-1 may dramatically
inﬂuence astrocyte physiology.
Microglial cells, the resident immune cellswithin the brain,may
also be inﬂuenced by the decreased availability of IGF-1 in aged
animals. Once activated and recruited to the site of injury/damage,
microglia play a critical role in removing cellular debris from
the extracellular space. Interestingly, this phagocytic activity of
microglia is reduced in aged animals (Sheng et al., 1998; Njie et al.,
2012). We, and others, have reported an increase in the number of
activated microglia within the hippocampus of aged rats (Ogura
et al., 1994; Sheng et al., 1998; Mouton et al., 2002; Frank et al.,
2006; Miller and Streit, 2007; VanGuilder et al., 2011a). Moreover,
aging leads to increased expression of several microglial-speciﬁc
major histocompatibility complex class II (MHC-II) immune
response-associated genes and increased production of speciﬁc
cytokines (Perry et al., 1993; Frank et al., 2006; Grifﬁn et al., 2006;
VanGuilder et al., 2011a). This increased pro-inﬂammatory proﬁle
has led to the assumption that microglia underlie the sensitization
of the aged brain to neurodegeneration (Medzhitov, 2008; Wong,
2013). However, we ﬁnd no differences between the microglia
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of cognitively impaired aged animals and age-matched controls
(VanGuilder et al., 2011a).
Oligodendrocytes have a critical role in the regulation of
neuronal excitability since they are responsible for the ensheath-
ment of axons in myelin. Thus, alterations in oligodendrocyte
function can dramatically impair neuronal signaling. We have
previously reported an increase in myelination proteins in the
hippocampus of cognitively impaired aged rats (VanGuilder et al.,
2011b, 2012; VanGuilder Starkey et al., 2013b). This up-regulation
included an increase in myelin-associated proteins on the surface
of oligodendrocytes andneurons, includingmyelin-associated gly-
coprotein (MAG), myelin-oligodendrocyte glycoprotein (MOG),
and neurite outgrowth inhibitor (NOGO-A), as well as an increase
in the neuronal receptor complexes for these myelination pro-
teins, Nogo-66 receptor 1 (NgR1) and co-receptors p75, TROY
(a member of the Tumor necrosis factor receptor superfam-
ily, member 19, also known as TNFRSF19) and LRR and Ig
domain-containing, Nogo Receptor-interacting protein (LINGO-
1) (VanGuilder et al., 2011b, 2012; VanGuilder Starkey et al.,
2013b). Furthermore, we reported an age-related decrease in
antagonists of theNgR1myelination pathway (VanGuilder Starkey
et al., 2013a). While aging is often associated with demyelination,
genes associated with myelin turnover and the total number of
oligodendrocytes have been shown to increase with age (Blalock
et al., 2003; Peters and Sethares, 2004). Thus, it has been sug-
gested that the increased proliferation of oligodendrocytes may
be an attempt to compensate for demyelination (Peters and
Sethares, 2004). It is possible that the up-regulation of these
myelin-associated proteins observed in cognitively impaired aged
animals is an aberrant effort of both the oligodendrocytes and
neurons to restore oligo-neuronal communication/myelination
that ultimately results in a loss of long-range cortical associa-
tion pathways and synaptic efﬁcacy. A loss of synaptic efﬁcacy
is also observed when IGF-1 is depleted. Interestingly, IGF-1
has been shown to have a protective role for oligodendrocytes,
as administration of IGF-1 is associated with a reduction of
oligodendrocyte apoptosis following a variety of insults (Ye and
D’Ercole, 1999; Mason et al., 2000; Cao et al., 2003; Lin et al.,
2005). Besides these limited studies, the inﬂuence of IGF-1
on oligodendrocytes remains largely unknown. Thus, as with
the other glial cells, further work is required to delineate the
impact of the age-associated decrease in IGF-1 on oligodendrocyte
physiology.
SYNAPTIC DYSFUNCTION, AGING, AND IGF-1
In both human and animal models, deﬁcits of executive function
as well as spatial learning and memory are manifest in a signiﬁcant
percent of the aged population. Although alterations in the func-
tion of glial cells and elements of the cardiovascular system with
age certainly contribute to these effects as discussed above, there
is no comprehensive understanding of how these changes result
in cognitive impairment. Furthermore it is clear that there are
many morphological and biochemical changes that occur in the
CNS of the elderly but these changes may not be directly asso-
ciated with impaired function. Interestingly, increased activity
of neuronal circuits in the aged brain may have a compensatory
role and could compensate (although most likely less effectively)
for the loss of important cognitive tasks, as described in detail
for the Scaffolding Theory of brain aging. This theory was pro-
posed to explain the increased “frontal activation with age as a
marker of the adaptive brain that engages in compensatory scaf-
folding [development of alternative neural circuitry] in response
to the challenges posed by declining neural structures and func-
tion” (Park and Reuter-Lorenz, 2009). Studies on brains from a
variety of mammalian species including humans conclude that
ultimately a reduced number of synaptic connections among neu-
rons are themost consistent correlatewith aging (Brunso-Bechtold
et al., 2000; Peters et al., 2008; Giorgio et al., 2010; Soghomonian
et al., 2010; VanGuilder et al., 2010; Peters and Kemper, 2011) and
cognitive decline (Dickson et al., 1995; Scheff et al., 2006; Van-
Guilder et al., 2011b). This ﬁnding was emphasized in our recent
studies on the altered expression of a set of neurotransmission-
regulating proteins with age (VanGuilder et al., 2010, 2011b).
Even more recently, our data indicate that age-related cognitive
impairment is closely associated with a speciﬁc set of synaptic
proteins with roles in functional and structural plasticity (Van-
Guilder and Freeman, 2011). For example, we recently reported a
decrease in calcium/calmodulin-dependent protein kinase II alpha
(αCaMKII) expressionwithin cognitively impaired aged rats (Van-
Guilder et al., 2011b). Because CaMKII plays a critical role in the
induction and maintenance of LTP (Lisman, 1994; Malenka and
Nicoll, 1999; Hudmon and Schulman, 2002), the loss of CaMKII
activity may underlie the decreased synaptic plasticity/efﬁcacy in
cognitively impaired aged animals. Indeed, this concept is sup-
ported by studies in the αCaMKII knockout mice, which exhibit
an accelerated decline of the ability to induce LTP with animal
age (Kirkwood et al., 1997). Taken together these results warrant
a closer investigation of the synaptic transmission and its vulner-
ability with age as the best candidate mechanism for cognitive
decline in the elderly.
SYNAPTIC TRANSMISSION AND ITS ROLE IN LEARNING AND MEMORY
There are three major components of the synapse: the pre-
synaptic site, the synaptic cleft and the post-synaptic site. The
pre-synaptic site is activated by a depolarizing action potential,
which opens voltage-gated calcium channels. The result is cal-
cium ion inﬂux into the terminal or synaptic bouton. Elevated
intracellular calcium ion concentrations trigger the exocytosis
machinery that consists of calcium sensors (synaptotagmins),
SNARE (soluble NSF attachment protein receptor) proteins
[synaptobrevin/vesicle-associated membrane protein (VAMP),
syntaxin-1, and synaptosomal-associated protein 25 (SNAP-25)]
and other regulatory binding partners (rab3, rabphilin, munc13,
and munc18) that are essential for the proper spatial and tempo-
ral execution of synaptic vesicle fusion at the active zone (Fujita
et al., 1996; Verhage et al., 2000; Schoch et al., 2001; Washbourne
et al., 2002; Deák et al., 2004, 2006, 2009; Bronk et al., 2007; Süd-
hof and Rothman, 2009). Lipid membranes of the vesicle and
the plasma membrane are forced into close proximity creating a
fusion pore through which the neurotransmitter molecules are
released into the cleft. Diffusion of small neurotransmitters (e.g.,
glutamate and gamma-aminobutyric acid, GABA) through the
narrow synaptic gap allows the neurotransmitters to bind selec-
tively to their receptors on the post-synaptic site. The two major
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classes of post-synaptic receptors are ionotropic (functioning as
ion channels) and metabotropic (communicating with intracel-
lular G protein signals). For the excitatory transmitter glutamate,
the ionotropic receptors are divided into three groups according to
speciﬁc agonists; AMPA (2-amino-3-(5-methyl-3-oxo-1,2-oxazol-
4-yl)propanoic acid), NMDA (N-methyl-D-aspartic acid), and
kainate receptors. For the inhibitory GABA transmitter, the
ionotropic receptor is referred to as GABA-A-type while the
metabotropic receptor is GABA-B-type. Research studies over
the past several decades indicate that learning modiﬁes synap-
tic strength and that these molecular changes are responsible for
memory formation. This increase in synaptic strength is termed
LTP (Bliss and Collingridge, 1993). LTP was initially discovered
in hippocampal excitatory synaptic connections (Bliss and Lomo,
1973) but is a ubiquitous phenomenon in a wide variety of brain
regions andoccurs atmanydifferent synaptic connections (includ-
ing inhibitory synapses; Bliss andCollingridge, 1993; Castillo et al.,
2011). The opposite effect leading to a permanent decrease in
synaptic strength is termed long-term depression (LTD).
Synaptic loss and/or alterations in synaptic function are con-
sidered to be the main pathological features of cognitive decline
in aging. Marked alterations of both the pre- and post-synaptic
structures with age were described both in human (Honer et al.,
1992; Dickson et al., 1995) and animalmodels (Adams et al., 2008).
The expression level of the pre-synaptic marker synaptophysin is
decreased in the elderly, which is likely the result of synapse loss.
Since synaptophysin is a critical synaptic vesicular protein, reduced
levels of this protein can be alternatively interpreted as a decrease
in the number of vesicles in synaptic boutons, assuming the overall
number of synapses is unchanged. In addition, synaptic morphol-
ogy is altered consistentwith adecrease in overall synaptic function
(Adams et al., 2008). Studies indicate that synapses from older ani-
mals become weaker with induction of LTD and, as a result, these
animals aremore susceptible to reversal of LTP at synapses in brain
regions important for learning and memory (Norris et al., 1996;
Kumar et al., 2007). This phenomenon appears to be partly the
result of intracellular calcium signal dysregulation (Foster et al.,
2001) and also is associated with levels of oxidative stress in aged
neurons (Bodhinathan et al., 2010).
In addition to synaptic loss and LTD dysfunction, speciﬁc
post-synaptic NMDA receptors are down-regulated in aging rats
(Sonntag et al., 2000a; Adams et al., 2008; Liu et al., 2008). Learn-
ing deﬁcits are associated with changes in NMDA receptor subunit
expression in the hippocampalCA3ﬁeld (Adams et al., 2001,2008)
and these age-dependent changes can be reversed by systematic
IGF-1 treatment (Sonntag et al., 2000a,b, 2005; Adams et al., 2008)
suggesting that the effects of IGF-1 on learning and memory are
mediated, at least in part, throughmodulationof synaptic function
in general and, speciﬁcally, NMDA receptors.
NEURONAL SECRETION OF IGF-1
As previously described, 70% of circulating IGF-1 is under the
control of growth hormone (Sonntag et al., 2005). Interestingly,
production and secretion of IGF-1 by the CNS has been also
observed (Lund et al., 1986; Adamo et al., 1988; Rotwein et al.,
1988; Ayer-le Lievre et al., 1991) and brain-derived IGF-1 is
dependent on neuronal activity (Hughes et al., 1999). Recently
an important regulatory mechanism for IGF-1 secretion has been
reported (Cao et al., 2011). Examining synaptic transmission in
the olfactory bulb of synaptotagmin10 (syt10) knockoutmice, Cao
et al. (2011) demonstrated that syt10 is essential for IGF-1 release.
Their results suggest that syt10 is required to couple enhanced
neuronal ﬁring to IGF-1 release. Consequently, paracrine effects
of IGF-1 augment synaptic connections and the maturation of
developing neurons in the olfactory bulb. In syt10 knockout mice,
mitral and granule neurons are smaller with less extensive den-
dritic arborization and fewer synaptic connections. Importantly,
treatment with exogenous IGF-1 completely reverses the syt10
knockout phenotype. Taken together these data elegantly demon-
strate that IGF-1 is produced in neurons and stored in vesicles
containing syt10, which triggers exocytosis of the vesicles and
IGF-1 if dendritic calcium is sufﬁciently elevated during rapid
neuronal ﬁring. This study supports the conclusion that IGF-1
released from neurons effectively supports synapse formation and
dendritic arborization at least within the olfactory bulb.
Considering the speciﬁc IGF actions that probably depend on
neuron type, the local environment and the developmental stage
(see the severe CNS phenotype of the igf1−/− mouse described
in Section “Introduction”), more experimental data are clearly
required. Emerging research indicates that IGF-1 promotes mat-
uration of neuroblasts in the sub-ventricular zone and neuronal
migration to the olfactory bulb (Hurtado-Chong et al., 2009). To
what extent paracrine IGF-1 is necessary for neurogenesis in other
parts of the brain remains to be understood and is beyond the
scope of this paper but we refer to other recent excellent reviews
on this context (Llorens-Martin et al., 2008;O’Kusky andYe,2012).
ACUTE SYNAPTIC EFFECTS OF IGF-1
Although the effects of IGF-1 are generally considered to
result from long-term exposure, acute application of des-IGF-1
(40 ng/ml, lacking the ﬁrst three amino residues from the N-
terminal of the peptide, that is not necessary for IGF-1 receptor
binding) increases ﬁeld excitatory post-synaptic potential (EPSP)
amplitudes by 40% in the CA1 ﬁeld of hippocampal slices from
young rats (Ramsey et al., 2005). The enhancement is selective
to current through AMPA receptors, reversible and dependent
on phosphoinositide 3-kinase (PI3K) pathway activation. Fur-
thermore, IGF-1 administration acutely affects calcium currents
through L- and N-type voltage-gated channels (Blair and Mar-
shall, 1997) of cerebellar granule cells. Augmentation of current
through these calcium channels is voltage-dependent and selective
since P/Q and R-type channels are unaffected. The effect on N-
type channels is independent of Akt signaling whereas Akt kinase
activity is essential for the potentiation of L-type currents (Blair
et al., 1999) through phosphorylation of the L-type alpha1 subunit
at Y2122 by PI3K/Akt pathways (Bence-Hanulec et al., 2000). Our
preliminary data on hippocampal neurons offers further insight
into the acute effect of IGF-1 on synaptic transmission. We have
found that recycling of synaptic vesicles is signiﬁcantly increased
after application of des-IGF-1 (50 ng/ml; Deak, Ungvari and Son-
ntag, unpublished results). This is the ﬁrst indication of direct
enhancement of pre-synaptic neurotransmitter exocytosis by IGF-
1. Further mechanistic insight at the molecular level will clarify the
role of IGF-1 in synaptic transmission.
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POTENTIALLY ALTERNATIVE ACTIONS OF IGF-1 ON BRAIN
AGING: IGF-1-DEFICIENT DWARF ANIMALS
Despite the numerous primary studies and reviews detailing the
importance of adequate levels of circulating IGF-1 for healthy
aging, the role of this potent anabolic hormone in the genesis
of the aging phenotype remains controversial. Initially, the age-
related decrease in IGF-1 was considered to contribute to many
aspects of aging including, but not limited to, accumulation of fat
mass, cardiovascular dysfunction, as well as the decline in immune
function, cellular protein synthesis, and muscle mass. Later stud-
ies (as reviewed above) indicated that reduction in levels of IGF-1
has an important role in the decline in cognitive function and
increased risk for neurodegenerative diseases and stroke. Despite
the clear evidence that IGF-1 deﬁciency is a contributing factor in
speciﬁc aging phenotypes, subsequent studies revealed that some,
but not all, rodentmodelswith impaired IGF-1 signaling exhibit an
increased life span. Based on studies initially conducted in inver-
tebrate organisms, such as Caenorhabditis elegans and Drosophila
melanogaster (Kenyon et al., 1993; Kimura et al., 1997; Kenyon,
2001), the corresponding data in mutant and transgenic mouse
models supported the conclusion that IGF-1 signaling is part of
a “conserved mechanism of aging” with decreased levels of IGF-1
delaying, rather than accelerating, the aging process (Brown-Borg
et al., 1996; Bartke and Brown-Borg, 2004). Thus, two disparate
concepts evolved and remain present in the literature (a) that
the presence of normal levels of IGF-1 accelerate aging and these
absence of IGF-1 or disruption of the IGF-1 signaling pathways
exert “anti-aging” effects and (b) that the age-related decline in
IGF-1 contribute to the deterioration of physiological function
and replacement of these hormones delay or reverse the aging
phenotype. A thorough discussion of these competing viewpoints
of IGF-1 action is found in recent reviews (Deak and Sonntag,
2012; Sonntag et al., 2012; Ungvari and Csiszar, 2012). Unfor-
tunately, the primary barriers to reconciling the disparate views
of IGF-1 are that they challenge our understanding of the rela-
tionship between pathology and aging, the nature of conserved
mechanisms of aging, and the importance of “life span” changes
in the levels of these hormones that occur throughout the life span.
These conceptual differences have been exacerbated by numerous
studies that draw conclusions related to aging and life span based
on a low number of experimental animals, suboptimal animal
husbandry, and/or the absence of end-of-life pathology to cor-
roborate the conclusions. The result is a plethora of studies that
provide varying levels of support for the hypothesis that IGF-1
deﬁciency increases life span.
Importantly, the role and relevance of circulating IGF-1 for
brain aging has also produced conﬂicting results. In mice exhibit-
ing a deﬁciency in circulating IGF-1, brain IGF-1 levels are
actually normal and these animals appear to have normal cognitive
function (Kinney et al., 2001; Sun et al., 2005). The speciﬁc source
of brain IGF-1 has not been thoroughly investigated but likely
is derived from the vasculature, neurons, or glia. Nevertheless,
these results providing compelling support for the conclusion that
paracrine-derived IGF-1 is induced in these models and support
normal function of the brain into old age. Furthermore, the gen-
erally accepted interpretation that IGF-1 deﬁciency is a conserved
pathway for aging and that animals with a deﬁciency in circulating
IGF-1 exhibit a reduction in IGF-1 levels at the tissue level need to
be reconsidered. These are areas for future research studies.
CONCLUSION
IGF-1 has profound actions on the cerebrovasculature, glia and
neurons yet we are just beginning to understand the complex
effects of this hormone and the role of IGF-1 in managing the
important interactions that occur between these cell types. To
date, the importance of adequate levels of IGF-1 for maintenance
of brain health has been established for rodents, non-human pri-
mates, and humans, supporting the fundamental role of IGF-1 in
aging and, more speciﬁcally, cognitive decline. Additionally, we
are just beginning to understand the role of IGF-1 deﬁciency in
hypertension-induced pathology in the vascular system. Despite
the wealth of information that is currently available, many ques-
tions remain. For example, the regulation of paracrine IGF-1
secretion (as noted in the previous paragraph) is only begin-
ning to be understood and the relationship between circulating
IGF-1 and the local production of IGF-1 remain unknown. The
sources of IGF-1 that regulate brain function remain vague and
the conditions that regulate IGF-1 secretion from these sources
have not been established. The diverse actions of IGF-1 on multi-
ple brain tissues and systems demonstrate that brain aging and
the resulting decline in cognitive function cannot be viewed
through the lens of a single cell type or tissue. Rather, only
by investigating the interactions between endocrine, vascular
and brain will we understand the etiology of cognitive decline
with age.
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